Biochemical approaches to assess the impact of post-translational modifications on pathogenic tau conformations using recombinant protein

Abstract

Tau protein is associated with many neurodegenerative disorders known as tauopathies. Aggregates of tau are thought of as a main contributor to neurodegeneration in these diseases. Increasingly, evidence points to earlier, soluble conformations of abnormally modified monomers and multimeric tau as toxic forms of tau. The biological processes driving tau from physiological species to pathogenic conformations remain poorly understood, but certain avenues are currently under investigation including the functional consequences of various pathological tau changes (e.g. mutations, post-translational modifications (PTMs), and protein–protein interactions). PTMs can regulate several aspects of tau biology such as proteasomal and autophagic clearance, solubility, and aggregation. Moreover, PTMs can contribute to the transition of tau from normal to pathogenic conformations. However, our understating of how PTMs specifically regulate the transition of tau into pathogenic conformations is partly impeded by the relative lack of structured frameworks to assess and quantify these conformations. In this review, we describe a set of approaches that includes several in vitro assays to determine the contribution of PTMs to tau's transition into known pathogenic conformations. The approaches begin with different methods to create recombinant tau proteins carrying specific PTMs followed by validation of the PTMs status. Then, we describe a set of biochemical and biophysical assays that assess the contribution of a given PTM to different tau conformations, including aggregation, oligomerization, exposure of the phosphatase-activating domain, and seeding. Together, these approaches can facilitate the advancement of our understanding of the relationships between PTMs and tau conformations.

EFhd2 co-aggregates with monomeric and filamentous tau in vitro

“…Additionally, we demonstrated that EFhd2 does not affect ARA-induced tau filament formation. Thus, EFhd2 is a tau-associated protein that induces the formation of entangled tau filaments (Alhadidy and Kanaan, 2024). Nonetheless, it is worth mentioning that pathological tau also undergoes diverse molecular changes, including phosphorylation, acetylation, truncation, and other modifications, which could contribute to its aggregation.…”